• Markets
    • icon
  • Companies
ANP · ASX

Antisense Therapeutics Limited (ASX:ANP)

AU$0.057

 0.0 (0.0%)
ASX:Live
05/12/2023 04:10:44 PM
HALO Ords HALO Earnings Momentum HALO Consensus Value HALO Balance Sheet GROWTH AUS +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ANP Overview

ANP Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About ANP

Website

Antisense Therapeutics Limited

Telephone

61.3.9827.8999

Address

Level 1 14 Wallace Avenue Toorak, Victoria (VIC) 3142

Description

Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.

ANP Price Chart

Key Stats

Market Cap

AU$51.39M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.05 - 0.11

Trade Value (12mth)

AU$9,203.00

1 week

-5%

1 month

0%

YTD

-41.24%

1 year

-33.72%

All time high

1.848

Key Fundamentals

EPS 3 yr Growth

30.800%

EBITDA Margin

N/A

Operating Cashflow

-$8m

Free Cash Flow Return

-52.10%

ROIC

-72.70%

Interest Coverage

-1,624.90

Quick Ratio

4.50

Other Data

Shares on Issue (Fully Dilluted)

669m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ANP Announcements

Latest Announcements

Date Announcements

31 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 22

Change of Registry Address

×

Change of Registry Address

31 October 19

Annual Report

×

Annual Report

31 October 08

Results of 2008 Annual General Meeting

×

Results of 2008 Annual General Meeting

31 August 22

Appendix 4E and Full Year Statutory Accounts

×

Appendix 4E and Full Year Statutory Accounts

30 September 15

Annual Report to shareholders

×

Annual Report to shareholders

30 October 18

Investor Presentation

×

Investor Presentation

30 October 17

ATL1102 Black Hole MS Data Presented at Gobal Conference

×

ATL1102 Black Hole MS Data Presented at Gobal Conference

30 November 23

Notification regarding unquoted securities - ANP

×

Notification regarding unquoted securities - ANP

30 November 23

Change of Director's Interest Notice (CG,JG)

×

Change of Director's Interest Notice (CG,JG)

30 August 17

ATL1102 Black Hole MS data to be presented at MS Conference

×

ATL1102 Black Hole MS data to be presented at MS Conference

30 April 09

ATL/TV1102 Phase IIa data presented at AAN Annual Meeting

×

ATL/TV1102 Phase IIa data presented at AAN Annual Meeting

29 September 22

Change of Director's Interest Notice (GP)

×

Change of Director's Interest Notice (GP)

29 September 20

Antisense to present new data at WMS Virtual Congress 2020

×

Antisense to present new data at WMS Virtual Congress 2020

29 October 21

2021 Annual Report

×

2021 Annual Report

29 October 20

Annual Report

×

Annual Report

29 October 18

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

29 November 18

AGM Presentation

×

AGM Presentation

29 November 17

AGM Presentation

×

AGM Presentation

29 May 19

Updated Investor Presentation

×

Updated Investor Presentation

29 April 22

Change of Director's Interest Notice (CG,MD)

×

Change of Director's Interest Notice (CG,MD)

29 April 22

Bonus Options Issue - Letter to Shareholders

×

Bonus Options Issue - Letter to Shareholders

28 September 23

Publication of final Long COVID data for ATL1102

×

Publication of final Long COVID data for ATL1102

28 September 17

Annual Report

×

Annual Report

28 October 13

ANP to Present at Australia Biotech Invest 2013

×

ANP to Present at Australia Biotech Invest 2013

28 October 08

ANP to Present at Rodman and Renshaw Healthcare Conference

×

ANP to Present at Rodman and Renshaw Healthcare Conference

28 June 22

Proteomics and disease marker identification in DMD Webinar

×

Proteomics and disease marker identification in DMD Webinar

28 July 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

ANP Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.01 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.01 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -14.6 38.3 -84.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -65.9 27.0 -96.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.5 -16.4 -20.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.03 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.03 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 7.6 217.1 -52.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 541 634 669 Lock Lock Lock
Basic m Lock Lock Lock Lock 541 634 669 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 9 8 13 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 4.0 13.6 -6.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -9 -8 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.8 12.3 -76.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -9 -8 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.3 12.3 -75.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -9 -8 -13 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -2 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -8 -6 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -36.4 27.9 -95.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -6 -8 -8 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 8 21 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -6 -8 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -47.7 -33.7 -4.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 6 19 11 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 7 22 13 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -6 -19 -11 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 3 Lock Lock Lock
Equity $m Lock Lock Lock Lock 6 21 10 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 6 21 10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 30.8 257.3 -52.9 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -115.1 -25.9 -88.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -140.7 -27.5 -114.1 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -162.3 -55.5 -84.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -153.4 -42.7 -72.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -111.0 -57.3 -52.1 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -799.3 -631.7 -1,624.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.7 2.5 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -99.8 -89.9 -108.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 6.4 19.1 4.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 6.4 19.1 4.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 89.9 86.6 86.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -558.0 -672.4 -289.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -115.1 -25.9 -88.6 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.1 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -140.7 -27.5 -114.1 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -140.7 -27.5 -114.1 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 468.0 999.2 2,596.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -468.0 -999.2 -2,596.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ANP Shortsell

Frequently Asked Questions

The current share price of Antisense Therapeutics Limited (ANP:ASX) is AU$0.057.
The 52-week high share price for Antisense Therapeutics Limited (ANP:ASX) is AU$0.11.
The 52-week low share price for Antisense Therapeutics Limited (ANP:ASX)? is AU$0.05.
Antisense Therapeutics Limited (ANP:ASX) does not pay a dividend.
Antisense Therapeutics Limited (ANP:ASX) does not pay a dividend.
Antisense Therapeutics Limited (ANP:ASX) has a franking level of 0%.
Antisense Therapeutics Limited (ANP:ASX) is classified in the Healthcare.
The current P/E ratio for Antisense Therapeutics Limited (ANP:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.